论文部分内容阅读
AIM:To evaluate the clinicopathological features ofcolorectal cancer(CRC)with a v-Raf murine sarcomaviral oncogene homolog B1(BRAF)mutation and itsmolecular interaction with microsatellite instability(MSI)and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog(KRAS)in patients with advanced CRCs.METHODS:From October 2009 to December 2011,141 patients with stageⅢ(n=51)orⅣ(n=90)CRCs who were tested for the BRAF mutation at Severance Hospital were included.Among 141 patients,fivewere excluded due to follow-up loss.Therefore,136patients were included in the study.The clinicopathological data,MSI status,and KRAS/BRAF mutation status were reviewed retrospectively.In addition,to evaluating the value of BRAF mutation status,progressionfree survival and overall survival in all patients werecollected and compared between the BRAF wild-typegroup and BRAF mutation group.RESULTS:Of 136 patients,80(58.8%)were male and the mean age was 59 years.BRAF and KRAS mutations were detected in 9.6%and 35.3%of patients,respectively.Only 4.3%of patients had MSIhigh tumors and there were no MSI-high in tumors with a BRAF mutation.BRAF mutations tended to be more frequent in stageⅣthan in stageⅢ(11.76%vs 5.88%,P=0.370).Patients with a BRAF mutation had a lower incidence of KRAS mutation than those without(7.69%vs 38.21%,P=0.033).Overall survival was significantly shorter in the BRAF mutation group than in the BRAF wild-type group both by univariate analysis(P=0.041)and multivariate analysis(HR=2.195;95%CI:1.039-4.640;P=0.039),while progression-free survival was not different according to BRAF mutation status.CONCLUSION:CRCs with a BRAF mutation have distinct molecular features and resulted in a poor prognosis in Korean patients with advanced CRC.
AIM: To evaluate the clinicopathological features of colorectal cancer (CRC) with a v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation and its molecular interaction with microsatellite instability (MSI) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog in patients with advanced CRCs.METHODS: From October 2009 to December 2011, 141 patients with stage III (n = 51) orⅣ (n = 90) CRCs who were tested for the BRAF mutation at Severance Hospital were included. Among 141 patients, fivewere excluded due to follow-up loss.Therefore, 136patients were included in the study. clinicopathological data, MSI status, and KRAS / BRAF mutation status were reviewed retrospectively. In addition, to evaluating the value of BRAF mutation status, progressionfree survival and overall survival All patients were collected and compared between the BRAF wild-type and BRAF mutation groups. RESULTS: Of 136 patients, 80 (58.8%) were male and the mean age was 59 years. BRF and KRAS mutations were detected in 9.6% and 35 .3% of patients, respectively. Only 4.3% of patients with MSI high tumors and there were no MSI-high in tumors with a BRAF mutation. BRRAF mutations tended to be more frequent in stage IV dohan in stage III (11.76% vs 5.88%, P = 0.370). Patients with a BRAF mutation had a lower incidence of KRAS mutation than those without (7.69% vs 38.21%, P = 0.033). Overall survival was significantly shorter in the BRAF mutation group than in the BRAF wild-type group both by while progression-free survival was not different according to BRAF mutation status. CONCLUSION: CRCs with a BRAF mutation have a significant difference (p = 0.041) and multivariate analysis (HR = 2.195; 95% CI: 1.039-4.640; distinct molecular features and resulted in a poor prognosis in Korean patients with advanced CRC.